rosuvastatin calcium

FDA Drug Profile — Rosuvastatin Calcium

rosuvastatin calcium is listed in the FDA National Drug Code directory with 16 NDC codes, marketed under brand name including Rosuvastatin Calcium. Available dosage form: tablet, film coated.

Drug details

Generic Name
rosuvastatin calcium
Brand Names
Rosuvastatin Calcium
Application Number
ANDA212059
Sponsor
Zhejiang Yongtai Pharmaceutical Co., Ltd.
NDC Codes
16
Dosage Forms
TABLET, FILM COATED
Routes
ORAL
Active Ingredients
ROSUVASTATIN CALCIUM

Indications and Usage

1 INDICATIONS AND USAGE Rosuvastatin tablets are indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and at least one additional CV risk factor. As an adjunct to diet to: O Reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia. O Reduce LDL-C and slow the progression of atherosclerosis in adults. O Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: O Primary dysbetalipoproteinemia. O Hypertriglyceridemia. Rosuvastatin tablets are an HMG Co-A reductase inhibitor (statin) indicated: ( 1 ) To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and at least one additional CV risk factor. As an adjunct to diet to: O reduce LDL-C in adults with primary hyperlipidemia. O reduce LDL-C and slow the progression of atherosclerosis in adults. O reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: O Primary dysbetalipoproteinemia. O Hypertriglyceridemia.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.